Interactions Between the Metabolic Reprogramming of Liver Cancer and Tumor Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Mar 3

PMID 40028341

Authors

Haoqiang Yang

Jinghui Li

Yiting Niu

Tao Zhou

Pengyu Zhang

Yang Liu

Yanjun Li

Affiliations

Soon will be listed here.

Abstract

Metabolic reprogramming is one of the major biological features of malignant tumors, playing a crucial role in the initiation and progression of cancer. The tumor microenvironment consists of various non-cancer cells, such as hepatic stellate cells, cancer-associated fibroblasts (CAFs), immune cells, as well as extracellular matrix and soluble substances. In liver cancer, metabolic reprogramming not only affects its own growth and survival but also interacts with other non-cancer cells by influencing the expression and release of metabolites and cytokines (such as lactate, PGE2, arginine). This interaction leads to acidification of the microenvironment and restricts the uptake of nutrients by other non-cancer cells, resulting in metabolic competition and symbiosis. At the same time, metabolic reprogramming in neighboring cells during proliferation and differentiation processes also impacts tumor immunity. This article provides a comprehensive overview of the metabolic crosstalk between liver cancer cells and their tumor microenvironment, deepening our understanding of relevant findings and pathways. This contributes to further understanding the regulation of cancer development and immune evasion mechanisms while providing assistance in advancing personalized therapies targeting metabolic pathways for anti-cancer treatment.

References

Sugiura A, Rathmell J . Metabolic Barriers to T Cell Function in Tumors. J Immunol. 2018; 200(2):400-407. PMC: 5777533. DOI: 10.4049/jimmunol.1701041. View

Missiaen R, Anderson N, Kim L, Nance B, Burrows M, Skuli N . GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 2022; 34(8):1151-1167.e7. PMC: 9357184. DOI: 10.1016/j.cmet.2022.06.010. View

Calle R, Amin N, Carvajal-Gonzalez S, Ross T, Bergman A, Aggarwal S . ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 2021; 27(10):1836-1848. DOI: 10.1038/s41591-021-01489-1. View

Dang C, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21):6479-83. PMC: 2783410. DOI: 10.1158/1078-0432.CCR-09-0889. View

Safrhansova L, Hlozkova K, Starkova J . Targeting amino acid metabolism in cancer. Int Rev Cell Mol Biol. 2022; 373:37-79. DOI: 10.1016/bs.ircmb.2022.08.001. View

Yamamoto J, Inubushi S, Han Q, Tashiro Y, Sugisawa N, Hamada K . Linkage of methionine addiction, histone lysine hypermethylation, and malignancy. iScience. 2022; 25(4):104162. PMC: 9010622. DOI: 10.1016/j.isci.2022.104162. View

Boomer J, Green J . An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010; 2(8):a002436. PMC: 2908766. DOI: 10.1101/cshperspect.a002436. View

Chapman N, Boothby M, Chi H . Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2019; 20(1):55-70. DOI: 10.1038/s41577-019-0203-y. View

Casadei-Gardini A, Del Coco L, Marisi G, Conti F, Rovesti G, Ulivi P . H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. Cancers (Basel). 2020; 12(1). PMC: 7016798. DOI: 10.3390/cancers12010241. View

10.

Yip-Schneider M, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks P . Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas. 2008; 37(3):e45-53. DOI: 10.1097/MPA.0b013e318172b4dd. View

11.

Wilde L, Roche M, Domingo-Vidal M, Tanson K, Philp N, Curry J . Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development. Semin Oncol. 2017; 44(3):198-203. PMC: 5737780. DOI: 10.1053/j.seminoncol.2017.10.004. View

12.

Zhu G, Tang Z, Huang R, Qu W, Fang Y, Yang R . CD36 cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023; 9(1):25. PMC: 9988869. DOI: 10.1038/s41421-023-00529-z. View

13.

Hu X, Chen Z, Wang Z, Xiao Q . Cancer evolution: Special focus on the immune aspect of cancer. Semin Cancer Biol. 2022; 86(Pt 2):420-435. DOI: 10.1016/j.semcancer.2022.05.006. View

14.

Geiger R, Rieckmann J, Wolf T, Basso C, Feng Y, Fuhrer T . L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. 2016; 167(3):829-842.e13. PMC: 5075284. DOI: 10.1016/j.cell.2016.09.031. View

15.

Kim Y, Jeong D, Pak K, Han M, Kim J, Liangwen L . SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget. 2017; 8(40):68381-68392. PMC: 5620264. DOI: 10.18632/oncotarget.20266. View

16.

Devillier R, Chretien A, Pagliardini T, Salem N, Blaise D, Olive D . Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. J Leukoc Biol. 2020; 109(6):1071-1088. DOI: 10.1002/JLB.5MR0920-198RR. View

17.

Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T . Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020; 14(3):539-555. PMC: 7053238. DOI: 10.1002/1878-0261.12629. View

18.

Chen Y, Choi S, Michelotti G, Chan I, Swiderska-Syn M, Karaca G . Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterology. 2012; 143(5):1319-1329.e11. PMC: 3480563. DOI: 10.1053/j.gastro.2012.07.115. View

19.

Xing Y, Li M, Tao L, Ruan L, Hong W, Chen C . Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by H NMR Based Metabolic Profiling. J Proteome Res. 2018; 17(5):1943-1952. DOI: 10.1021/acs.jproteome.8b00029. View

20.

DeWaal D, Nogueira V, Terry A, Patra K, Jeon S, Guzman G . Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 2018; 9(1):446. PMC: 5792493. DOI: 10.1038/s41467-017-02733-4. View